(19) JAPANESE PATENT OFFICE

PATENT ABSTRACTS OF JAPAN

(11) Publication number: **2003277262 A**
(43) Date of publication of application: **02.10.2003**

(51) Int. Cl **A61K 31/4439**
A61K 9/08, A61K 47/14, A61P 1/04

(21) Application number: **2002075138**
(22) Date of filing: **18.03.2002**

(71) Applicant: **TAKADA KANJI**
(72) Inventor: **TAKADA KANJI**

(54) TECHNIQUE OF IMPROVING BIOAVAILABILITY OF LANSOPRASOLE

(57) Abstract:

PROBLEM TO BE SOLVED: To provide a novel oral preparation technique of enhancing the solubility and absorbability of lansoprasole in the digestive tract to reliably attain a therapeutically effective drug concentration in blood.

SOLUTION: The preparation is prepared by formulating lansoprasole with a mixture of a 6-18C fatty acid/glycerol ester with a 6-18C fatty acid/macrogol ester.

The Delphion Integrated View

Title: **JP2003277262A2: TECHNIQUE OF IMPROVING BIOAVAILABILITY OF LANSOPRASOLE**

Derwent Title: Lansoprazole formulation for use as anticancer agent, contains lansoprazole and ester mixture of glycerol- and macrogol-ester of fatty acid, and has increased bioavailability in digestive tract after oral administration [Derwent Record]

Country: **JP** Japan

Kind: **A2** Document Laid open to Public inspection



View Image

1 page

Inventor: **TAKADA KANJI**;

Assignee: **TAKADA KANJI**
News, Profiles, Stocks and More about this company

Published / Filed: **2003-10-02** / 2002-03-18

Application Number: **JP2002000075138**

IPC Code: Advanced: **A61K 9/08**; **A61K 31/4439**; **A61K 47/14**; **A61P 1/04**;
Core: **A61K 31/4427**; **A61P 1/00**; more...
IPC-7: **A61K 9/08**; A61K 31/4439; A61K 47/14; A61P 1/04;

Priority Number: 2002-03-18 **JP2002000075138**

Abstract: PROBLEM TO BE SOLVED: To provide a novel oral preparation technique of enhancing the solubility and absorbability of lansoprasole in the digestive tract to reliably attain a therapeutically effective drug concentration in blood.

SOLUTION: The preparation is prepared by formulating lansoprasole with a mixture of a 6-18C fatty acid/glycerol ester with a 6-18C fatty acid/macrogol ester.

COPYRIGHT: (C)2004,JPO

Family: None

Other Abstract Info: DERABS C2003-884852

Derwent Record

Derwent Title: **Lansoprazole formulation for use as anticancer agent, contains lansoprazole and ester mixture of glycerol- and macrogol-ester of fatty acid, and has increased bioavailability in digestive tract after oral administration**

Original Title: ☑ JP2003277262A2: TECHNIQUE OF IMPROVING BIOAVAILABILITY OF LANSOPRASOLE

Assignee: **TAKADA K** Individual

Inventor: **None**

Accession/ Update: **2003-884852 / 200382**

IPC Code: **A61K 31/4439** ; A61K 9/08 ; A61K 47/14 ; A61P 1/04 ;

Derwent Classes: **B02**;

Manual Codes: **B04-C03**(Polymers [general]) , **B06-D05**(Heterocyclic fused ring with 2 rings (5+6 membered) and two N) , **B10-G02**(Carboxylic esters) , **B14-H01** (Anticancer general and other)

Derwent Abstract: (JP2003277262A2) **Novelty** - Dissolution-absorption of lansoprazole in the digestive tract after oral administration is increased by adding ester mixture of glycerol ester of 6-18C fatty acid and macrogol ester of 6-18C fatty acid with respect to lansoprazole.
ACTIVITY - Cytostatic.
No test details are given.
MECHANISM OF ACTION - None given.
Use - As anticancer agent.
Advantage - By adding the ester mixture, lansoprazole is absorbed reliably from the formulation and bioavailability of lansoprazole is increased sharply. Laparotomy was performed in Wistar male rat with body weight of 350 plus or minus 25 g under pentobarbital anesthesia. Suspension containing 5 mg of lansoprazole in 1 ml of 0.5% carboxymethylcellulose was poured into duodenum of rat at a dose of 5 mg/kg. Blood samples were collected from jugular vein after 30 minutes and 1-6 hours, and concentration of lansoprazole in plasma was measured by high performance liquid chromatography. Lansoprazole concentration (micro g/ml) in plasma was 0.15 plus or minus 0.03 (after 30 minutes), 0.21 plus or minus 0.05 (after 1 hour), 0.26 plus or minus 0.03 (after 2 hours), 0.22 plus or minus 0.06 (after 3 hours), 0.16 plus or minus 0.05 (after 4 hours), 0.11 plus or minus 0.04 (after 5 hours) and 0.05 plus or minus 0.02 (after 6 hours). The gentamycin concentration in plasma after administering control formulation to rat was 0.05 plus or minus 0.01 (after 2 hours). All other plasma samples showed concentration, which was less than detection limit (0.02 micro g/ml) after 30 minutes, 1 hour and 3-6 hours.

Dwg.0/0

Family:

PDF	Patent	Pub. Date	Derwent Update	Pages	Language	IPC Code
☑	JP2003277262A2 *	2003-10-02	200382	3	English	A61K 31/4439

Local appls.:

Priority Number:

Application Number	Filed	Original Title

JP2002000075138	2002-03-18	TECHNIQUE OF IMPROVING BIOAVAILABILITY OF LANSOPRASOLE

Chemical Indexing Codes: Show chemical indexing codes

Specific Compound Numbers: Show specific compounds

Related Accessions:

Accession Number	Type	Derwent Update	Derwent Title
C2003-252140	C		
1 item found			

Title Terms: FORMULATION ANTICANCER AGENT CONTAIN ESTER MIXTURE GLYCEROL ESTER FATTY ACID INCREASE DIGEST TRACT AFTER ORAL ADMINISTER

Pricing Current charges

Derwent Searches: Boolean | Accession/Number | Advanced